Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 9 |
| 1.1 List of Tables | 8 | 2 |
| 1.2 List of Figures | 10 | 3 |
| 2 Global Oncology Therapeutics Market: Introduction | 13 | 2 |
| 2.1 GBI Research Report Guidance | 14 | 1 |
| 3 Global Oncology Therapeutics Market: Cancer Epidemiology | 15 | 1 |
| 4 Global Oncology Therapeutics Market: Market Overview | 16 | 15 |
| 4.1 Introduction | 16 | 2 |
| 4.2 Revenue Forecasts for the Global Oncology Therapeutics Market | 18 | 1 |
| Sales Value | 18 | 1 |
| 4.2.2 Sales Volume | 19 | 1 |
| 4.2.3 Drug Prices | 20 | 1 |
| 4.2.4 Treatment Usage Patterns | 21 | 1 |
| 4.2.4.1 Diseased Population | 22 | 1 |
| 4.2.4.2 Treatment Seeking Population | 23 | 1 |
| 4.2.4.3 Diagnosis Population | 23 | 1 |
| 4.2.4.4 Prescription Population | 24 | 1 |
| 4.3 Generics in Oncology Therapeutics Market | 25 | 1 |
| 4.4 Oncology therapeutics market Drivers | 26 | 1 |
| 4.4.1 Steady Increase in the Ageing Population | 26 | 1 |
| 4.4.2 New Innovative Products in the Pipeline | 27 | 1 |
| 4.4.3 Rapid Uptake of Targeted Therapies in Key Cancer Indications | 27 | 1 |
| 4.5 Oncology Therapeutics Market Restraints | 27 | 1 |
| 4.5.1 The US Cancer Incidence Moving Towards a Decelerating Growth Rate | 27 | 1 |
| Patent Expirations and Entry of Generics Pose as a Severe Threat for Primary Manufacturers | 28 | 1 |
| 4.5.3 Restrictive Pricing and Reimbursement Policies Causing Serious Problems in the Oncology Therapeutics Market Growth | 29 | 1 |
| 4.5.4 More Than 80 Molecules to be Launched Over the Next Seven years - Leading to More Competition | 30 | 1 |
| 5 Global Oncology Therapeutics Market: Pricing and Reimbursement | 31 | 10 |
| 5.1 Average Cost of Drug Treatment | 31 | 2 |
| 5.2 The US | 33 | 1 |
| 5.2.1 Pricing | 33 | 1 |
| 5.2.2 Medicare Reimbursement on Cancer Drugs | 33 | 1 |
| 5.3 Europe | 34 | 2 |
| 5.3.1 Pricing and Reimbursement - Country Analysis | 36 | 1 |
| 5.3.1.1 United Kingdom | 36 | 1 |
| 5.3.1.2 Germany | 37 | 1 |
| 5.3.1.3 France | 38 | 1 |
| 5.3.1.4 Italy | 38 | 1 |
| 5.3.1.5 Spain | 39 | 2 |
| 6 Global Oncology Therapeutics Market: Geographical Landscape | 41 | 24 |
| 6.1 Geographic Break-up | 41 | 1 |
| 6.2 The US | 42 | 1 |
| 6.2.1 Sales Value | 42 | 1 |
| 6.2.2 Sales Volume | 43 | 1 |
| 6.2.3 Drug Prices | 44 | 1 |
| 6.2.4 Treatment Usage Patterns | 45 | 1 |
| 6.2.4.1 Diseased Population | 46 | 1 |
| 6.2.4.2 Treatment Seeking Population | 47 | 1 |
| 6.2.4.3 Diagnosis Population | 48 | 1 |
| 6.2.4.4 Prescription Population | 48 | 1 |
| 6.3 Top Five European Countries | 49 | 1 |
| 6.3.1 Sales Value | 49 | 2 |
| 6.3.2 Sales Volume | 51 | 1 |
| 6.3.3 Drug Prices | 51 | 2 |
| 6.3.4 Treatment Usage Patterns | 53 | 1 |
| 6.3.4.1 Diseased Population | 54 | 1 |
| 6.3.4.2 Treatment Seeking Population | 54 | 1 |
| 6.3.4.3 Diagnosis Population | 55 | 1 |
| 6.3.4.4 Prescription Population | 56 | 1 |
| 6.4 Japan | 57 | 1 |
| 6.4.1 Sales Value | 57 | 1 |
| 6.4.2 Sales Volume | 58 | 1 |
| 6.4.3 Drug Prices | 59 | 1 |
| 6.4.4 Treatment Usage Patterns | 60 | 1 |
| 6.4.4.1 Diseased Population | 61 | 1 |
| 6.4.4.2 Treatment Seeking Population | 62 | 1 |
| 6.4.4.3 Diagnosis Population | 63 | 1 |
| 6.4.4.4 Prescription Population | 63 | 2 |
| 7 Global Oncology Therapeutics Market: Therapeutic Landscape | 65 | 50 |
| 7.1 Breast Cancer Therapeutics Market | 65 | 1 |
| 7.1.1 Introduction | 65 | 1 |
| 7.1.1.1 Symptoms | 66 | 1 |
| 7.1.1.2 Treatment | 67 | 1 |
| 7.1.1.3 Epidemiology | 67 | 1 |
| 7.1.2 Sales Value | 67 | 1 |
| 7.1.3 Sales Volume | 68 | 1 |
| 7.1.4 Drug Prices | 69 | 1 |
| 7.1.5 Treatment Usage Patterns | 70 | 2 |
| 7.1.5.1 Diseased Population | 72 | 1 |
| 7.1.5.2 Treatment Seeking Population | 72 | 1 |
| 7.1.5.3 Diagnosis Population | 73 | 1 |
| 7.1.5.4 Prescription Population | 74 | 1 |
| 7.2 Non-Hodgkin s Lymphoma Therapeutics Market | 75 | 1 |
| 7.2.1 Introduction | 75 | 1 |
| 7.2.1.1 Symptoms | 75 | 1 |
| 7.2.1.2 Treatment | 75 | 1 |
| 7.2.1.3 Epidemiology | 76 | 1 |
| 7.2.2 Sales Value | 76 | 2 |
| 7.2.3 Sales Volume | 78 | 1 |
| 7.2.4 Drug Prices | 78 | 1 |
| 7.2.5 Treatment Usage Patterns | 79 | 2 |
| 7.2.5.1 Diseased Population | 81 | 1 |
| 7.2.5.2 Treatment Seeking Population | 81 | 1 |
| 7.2.5.3 Diagnosis Population | 82 | 1 |
| 7.2.5.4 Prescription Population | 83 | 1 |
| 7.3 Colorectal Cancer Therapeutics Market | 83 | 1 |
| 7.3.1 Introduction | 83 | 2 |
| 7.3.1.1 Symptoms | 85 | 1 |
| 7.3.1.2 Treatment | 85 | 1 |
| 7.3.1.3 Epidemiology | 86 | 1 |
| Sales Value | 87 | 1 |
| 7.3.3 Sales Volume | 88 | 1 |
| Drug Prices | 89 | 1 |
| 7.3.5 Treatment Usage Patterns | 90 | 1 |
| 7.3.5.1 Diseased Population | 91 | 1 |
| 7.3.5.2 Treatment Seeking Population | 92 | 1 |
| 7.3.5.3 Diagnosis Population | 92 | 1 |
| 7.3.5.4 Prescription Population | 93 | 1 |
| 7.4 Prostate Cancer Therapeutics Market | 94 | 1 |
| 7.4.1 Introduction | 94 | 1 |
| 7.4.1.1 Symptoms | 95 | 1 |
| 7.4.1.2 Treatment | 95 | 1 |
| 7.4.1.3 Epidemiology | 96 | 1 |
| 7.4.2 Sales Value | 96 | 1 |
| 7.4.3 Sales Volume | 97 | 1 |
| 7.4.4 Drug Prices | 98 | 1 |
| 7.4.5 Treatment Usage Patterns | 99 | 1 |
| 7.4.5.1 Diseased Population | 100 | 1 |
| 7.4.5.2 Treatment Seeking Population | 101 | 1 |
| 7.4.5.3 Diagnosis Population | 102 | 1 |
| 7.4.5.4 Prescription Population | 102 | 1 |
| 7.5 Lung Cancer Therapeutics Market | 103 | 1 |
| 7.5.1 Introduction | 103 | 1 |
| 7.5.1.1 Symptoms | 104 | 1 |
| 7.5.1.2 Treatment | 105 | 1 |
| 7.5.1.3 Epidemiology | 106 | 1 |
| 7.5.2 Sales Value | 107 | 1 |
| 7.5.3 Sales Volume | 108 | 1 |
| Drug Prices | 109 | 1 |
| 7.5.5 Treatment Usage Patterns | 109 | 2 |
| 7.5.5.1 Diseased Population | 111 | 1 |
| 7.5.5.2 Treatment Seeking Population | 112 | 1 |
| 7.5.5.3 Diagnosis Population | 113 | 1 |
| 7.5.5.4 Prescription Population | 114 | 1 |
| 8 Global Oncology Therapeutics Market: Pipeline Analysis | 115 | 19 |
| Introduction | 115 | 1 |
| 8.1.1 R&D Strategies | 116 | 1 |
| 8.2 R&D Trends | 117 | 1 |
| 8.2.1 Discovery of Unknown Mutations that Play Key Role in Cancers | 117 | 1 |
| 8.2.1.1 UTX The Key for Many Multiple Myeloma and Esophageal Cancer Cases | 117 | 1 |
| 8.2.1.2 Synthetic Lethality A New Mechanism of Cell Death | 117 | 1 |
| 8.2.1.3 Matrix Metalloproteinase 8 (MMP 8) Stimulation | 118 | 1 |
| 8.2.2 Pairing Therapeutics and Diagnostics | 118 | 1 |
| 8.3 Profiles of Key Late-Stage Drugs | 119 | 1 |
| 8.3.1 Angiogenesis and Multi-Targeted Kinase Inhibitors | 119 | 1 |
| 8.3.1.1 Zactima | 119 | 1 |
| 8.3.1.2 Pazopanib | 120 | 1 |
| 8.3.1.3 Axitinib | 120 | 1 |
| 8.3.2 Hsp90 Inhibitors | 121 | 1 |
| 8.3.2.1 IPI-504 | 121 | 1 |
| 8.3.2.2 KOS-953 | 122 | 1 |
| 8.3.3 Insulin-like Growth Factor Receptor Inhibitors | 122 | 1 |
| 8.3.3.1 CP-751,871(figitumumab) | 122 | 1 |
| 8.3.3.2 MK-0646 | 123 | 1 |
| 8.3.3.3 CB7630 | 123 | 1 |
| 8.3.4 Hedgehog Inhibitors | 124 | 1 |
| GDC-0499 | 124 | 1 |
| 8.3.5 Immuno-conjugates | 124 | 1 |
| 8.3.5.1 SGN-35 | 124 | 1 |
| 8.3.5.2 Trastuzumab-DM1 (T-DM1) | 124 | 1 |
| 8.3.5.3 CMC544 | 125 | 1 |
| 8.4 Insights into Most Promising Drugs | 125 | 1 |
| 8.4.1 Provenge | 125 | 1 |
| 8.4.1.1 Introduction | 125 | 1 |
| 8.4.1.2 Mechanism of Action | 125 | 1 |
| 8.4.1.3 Clinical Trial Management | 125 | 2 |
| 8.4.1.4 Follow-on Indications | 127 | 1 |
| 8.4.1.5 Market Potential | 127 | 1 |
| 8.4.2 Denosumab | 127 | 1 |
| 8.4.2.1 Introduction | 127 | 1 |
| 8.4.2.2 Mechanism of Action | 127 | 1 |
| 8.4.2.3 Clinical Trial Management | 128 | 1 |
| Market Potential | 129 | 1 |
| 8.4.3 Tasigna | 129 | 1 |
| 8.4.3.1 Introduction | 129 | 1 |
| 8.4.3.2 Mechanism of Action | 129 | 1 |
| 8.4.3.3 Clinical Trial Management | 129 | 1 |
| 8.4.3.4 Market Potential | 130 | 1 |
| 8.4.4 Aflibercept | 130 | 1 |
| 8.4.4.1 Introduction | 130 | 1 |
| 8.4.4.2 Mechanism of Action | 130 | 1 |
| 8.4.4.3 Clinical Trial Management | 131 | 1 |
| 8.4.4.4 Market Potential | 131 | 1 |
| 8.4.5 Tykerb | 131 | 1 |
| 8.4.5.1 Introduction | 131 | 1 |
| 8.4.5.2 Mechanism of Action | 131 | 1 |
| 8.4.5.3 Clinical Trial Management | 132 | 1 |
| 8.4.5.4 Market Potential | 133 | 1 |
| 9 Global Oncology Therapeutics Market: Competitive Landscape | 134 | 36 |
| 9.1 Evolving competitive landscape | 134 | 1 |
| 9.1.1 Major players | 135 | 1 |
| 9.1.2 Key areas focused for R&D | 135 | 1 |
| 9.1.3 Challenges faced by brands in marketing the oncology products | 136 | 2 |
| 9.2 Market Share Analysis | 138 | 1 |
| 9.2.1 Rituxan, Avastin, Revlimid and Herceptin are expected to lead the market through 2015 | 139 | 2 |
| 9.3 Roche/Genentech | 141 | 1 |
| 9.3.1 Key Oncology Drugs | 142 | 1 |
| 9.3.1.1 Rituxan | 142 | 1 |
| 9.3.1.2 Avastin | 143 | 1 |
| 9.3.1.3 Herceptin | 143 | 1 |
| 9.3.1.4 Tarceva | 144 | 1 |
| 9.3.1.5 Xeloda | 144 | 1 |
| 9.3.2 Key Indications of Interest | 145 | 1 |
| 9.3.3 Pipeline Analysis | 146 | 2 |
| 9.3.4 Key Strategies | 148 | 1 |
| 9.3.4.1 The Next Drug Generation: Small Molecule Conjugates | 148 | 1 |
| 9.3.4.2 Targeted Gene Silencing to Discover Drugs Which can Cure Cancer | 148 | 1 |
| 9.3.4.3 Mergers and Acquisitions An Excellent Strategy to Stay Competitive in the Market | 148 | 1 |
| 9.4 Novartis | 148 | 1 |
| 9.4.1 Key Oncology Drugs | 149 | 1 |
| 9.4.1.1 Gleevec | 149 | 1 |
| 9.4.1.2 Zometa | 150 | 1 |
| 9.4.1.3 Femara | 150 | 1 |
| 9.4.1.4 Sandostatin | 151 | 1 |
| 9.4.1.5 Exjade | 151 | 1 |
| 9.4.1.6 Tasigna | 151 | 1 |
| 9.4.2 Key Indications of Interest | 152 | 1 |
| 9.4.3 Pipeline Analysis | 152 | 1 |
| 9.4.4 Key Strategies | 153 | 1 |
| 9.4.4.1 Translational Science to Explore Multiple Disease Indications of Pipeline Drugs | 153 | 1 |
| 9.4.4.2 The Strategy of Drug Combinations Going to Play a Significant Role in Development Programs | 153 | 1 |
| 9.4.4.3 Biomarkers Development to Evaluate Safety and Efficacy of Pipeline Drugs | 154 | 1 |
| 9.4.4.4 Introducing Diagnostic Tests, Programs and Materials as a Package to Enhance Patient Adherence | 154 | 1 |
| 9.4.4.5 Maximizing Affordability and Sustainability of Drugs to Broader Group of Patients | 154 | 1 |
| 9.4.4.6 Focused Strategy for Drug Development | 154 | 1 |
| 9.4.4.7 Functional Genomics to Develop Breakthrough Technologies in Cancer Cure | 155 | 1 |
| 9.5 Sanofi-Aventis | 155 | 1 |
| 9.5.1 Key Oncology Drugs | 156 | 1 |
| 9.5.1.1 Taxotere | 156 | 1 |
| 9.5.1.2 Eloxatin | 157 | 1 |
| 9.5.2 Key Indications of Interest | 157 | 1 |
| 9.5.3 Pipeline Analysis | 158 | 1 |
| 9.5.4 Key Strategies | 159 | 1 |
| 9.6 Amgen | 160 | 1 |
| 9.6.1 Key Oncology Drugs | 161 | 1 |
| 9.6.1.1 Neulasta | 161 | 1 |
| 9.6.1.2 Neupogen | 162 | 1 |
| 9.6.1.3 Vectibix | 162 | 1 |
| 9.6.1.4 Denosumab | 162 | 1 |
| 9.6.2 Key of Indications of Interests | 163 | 1 |
| 9.6.3 Pipeline Analysis | 163 | 2 |
| 9.6.4 Key Strategies | 165 | 1 |
| 9.6.4.1 Replacement Value on Declining Drug Revenues | 165 | 1 |
| Continuance of its Own Old Strategies | 165 | 1 |
| 9.6.4.3 Reorientation of Research and Development Focus to Maximize Probability of Blockbuster drugs | 165 | 1 |
| 9.7 Astra Zeneca | 165 | 1 |
| 9.7.1 Key Oncology Drugs | 166 | 1 |
| 9.7.1.1 Arimidex | 166 | 1 |
| 9.7.1.2 Casodex | 166 | 1 |
| 9.7.1.3 Iressa | 167 | 1 |